@article{273e4478151e4dd9af95d2d047f39c5c,
title = "Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study",
abstract = "A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are warranted.",
keywords = "Genetic epidemiology, LRRK2, PARK16, Parkinson's disease",
author = "Lisa Wang and Heckman, {Michael G.} and Aasly, {Jan O.} and Grazia Annesi and Maria Bozi and Chung, {Sun Ju} and Carl Clarke and David Crosiers and Gertrud Eckstein and Gaetan Garraux and Hadjigeorgiou, {Georgios M.} and Nobu Hattori and Beom Jeon and Kim, {Yun J.} and Masato Kubo and Suzanne Lesage and Lin, {Juei Jueng} and Timothy Lynch and Peter Lichtner and Mellick, {George D.} and Vincent Mok and Morrison, {Karin E.} and Aldo Quattrone and Wataru Satake and Silburn, {Peter A.} and Leonidas Stefanis and Stockton, {Joanne D.} and Tan, {Eng King} and Tatsushi Toda and Alexis Brice and {Van Broeckhoven}, Christine and Uitti, {Ryan J.} and Karin Wirdefeldt and Zbigniew Wszolek and Georgia Xiromerisiou and Maraganore, {Demetrius M.} and Thomas Gasser and Rejko Kr{\"u}ger and Farrer, {Matthew J.} and Ross, {Owen A.} and Manu Sharma",
note = "Funding Information: The institution of L. Wang and M. Sharma is financially supported by the Courage-PD, an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND- www.jpnd.eu : the Medical Research Council, United Kingdom, the French National Research Agency, the German Bundesministerium f{\"u}r Bildung und Forschung, the Italian Ministry of Health/Ministry of Education, the Israeli Ministry of Health, the Luxembourgian National Research Fund, the Netherlands Organisation for Health Research and Development, the Research Council of Norway, the Portuguese Foundation for Science and Technology, the Spanish National Institute of Health Carlos III and Michael J. Fox Foundation. M. J. Farrer has a patent on genetic variability in LRRK2 and Parkinson's disease (US8409809, US8455243B2) and on LRRK2 mouse models subsequently developed with royalities paid. Nobutaka Hattori has been serving as an advisory board member for Boehringer Ingelheim, as a result of attending advisory board meetings he received personal compensation; he also has been serving as an advisory board member for FP Pharmaceutical Company, by attending these advisory meetings he received personal compensation and has been consulting with Ohtsuska Pharmaceutical Company, Kyowa Hakko Kirin Pharmaceutical Company, GlaxoSmithKline, Novartis, and Schering-Plough, and when he attended these advisory board meetings where he received personal compensation. Dr Gasser holds a patent concerning the LRRK2 gene and neurodegenerative disorders. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",
year = "2017",
month = jan,
day = "1",
doi = "10.1016/j.neurobiolaging.2016.09.022",
language = "English (US)",
volume = "49",
pages = "217.e1--217.e4",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}